MaxCyte's Board Transition: Art Mandell Retires with Legacy

MaxCyte Board Change: Honoring Art Mandell's Legacy

MaxCyte, Inc. (NASDAQ: MXCT), a pioneering company in cell engineering technologies, recently announced that long-serving board member Art Mandell has chosen to retire from his position on the Board of Directors effective December 31, 2024. Mr. Mandell's influence on the company began in 2006, positioning him as a key figure in its innovative growth.

Significant Achievements During Mandell's Tenure

Throughout his time on the Board, Mandell has witnessed and contributed to several remarkable milestones at MaxCyte. This includes the company’s successful initial public offering on the UK AIM exchange and its listing on the NASDAQ. Under his guidance, MaxCyte also launched its flagship ExPERT™ platform, which has proven essential in advancing cell and gene therapy. The company has amassed an impressive portfolio, securing 29 Strategic Platform Licenses and backing the first FDA-approved CRISPR edited non-viral cell therapy in the industry.

Expressions of Gratitude

Richard Douglas, chairman of the Board, expressed heartfelt thanks, stating, "We are deeply grateful for Art's exceptional leadership, scientific insights, and valuable contributions over the years." Mr. Mandell’s vision and strategic input have undeniably helped position MaxCyte as a frontrunner in the competitive field of cell engineering.

Art Mandell's Reflection on His Role

Mr. Mandell shared his sentiments regarding his time with MaxCyte, describing it as a privilege to serve on the Board. He expressed pride in the achievements the company has accomplished and confidence in its future ventures, particularly in delivering innovative solutions that support the development of groundbreaking cell and gene therapies.

A Glimpse into MaxCyte's Future

As MaxCyte moves forward with only nine remaining directors following Mandell's departure, the company remains focused on its mission to facilitate advanced cell therapies. With over 25 years of experience, MaxCyte has been at the forefront of cell engineering, equipping partners with cutting-edge tools and support to transform healthcare outcomes. The ExPERT™ platform, characterized by Flow Electroporation technology, supports the evolving cell therapy market and spans the entire lifecycle—from research through to commercialization.

MaxCyte’s Commitment to Innovation

The ExPERT family is not merely a technology platform; it consists of various products such as the ATx™, STx™, GTx™, and VLx™ instruments, along with proprietary processing assemblies and software protocols. MaxCyte's dedication to enhancing cell therapy aligns perfectly with the rising demand for effective and novel medicinal solutions in the healthcare landscape.

Maintaining Connections with Stakeholders

MaxCyte acknowledges the importance of staying connected with its partners and stakeholders. They offer robust scientific, technical, and regulatory support to their partners, ensuring that they are well-equipped to manage the challenge of developing transformative therapies.

Contacting MaxCyte

For those interested in learning more about the company and its innovative work, MaxCyte's website offers comprehensive resources. Stakeholders can reach out through designated channels for investment or media inquiries, ensuring that communication flows smoothly as the company continues to grow.

Frequently Asked Questions

Who is Art Mandell?

Art Mandell is a former board member of MaxCyte, Inc., having served since 2006 and played a key role in the company's strategic direction and growth.

What are some of MaxCyte's achievements during Mandell's time on the Board?

Under Mandell’s oversight, MaxCyte accomplished its IPOs on the UK AIM and NASDAQ and launched its ExPERT™ platform, claiming numerous strategic licenses.

What is the ExPERT™ platform?

The ExPERT™ platform is a leading technology solution by MaxCyte, facilitating cell engineering processes and supporting the development of cell and gene therapies.

How can I contact MaxCyte for inquiries?

For inquiries, you can reach out to MaxCyte via email or their official website to get information on their operations and ongoing projects.

What does the future hold for MaxCyte after Mandell's retirement?

MaxCyte aims to continue its innovative path in cell engineering with strong leadership and remains committed to delivering revolutionary solutions in cell therapies.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.